 Prognostic factors unselected patients nonseminomatous metastatic testicular cancer multicenter experience Between consecutive patients metastatic nonseminomatous testicular cancer Swedish Norwegian Testicular Cancer SWENOTECA project hospitals treatment plan chemotherapy cycles cisplatin vinblastine bleomycin surgical resection residual tumor masses median observation time months overall survival rate univariate analysis parameters prognosis extent disease Medical Research Council MRC prechemotherapy levels serum alpha-fetoprotein AFP human chorionic gonadotropin HCG lactate dehydrogenase LDH patients age presence extrapulmonary hematogeneous metastases large lymph node metastases Patients weeks orchiectomy start chemotherapy interval place treatment large oncology unit units significant prognostic factor patients large-volume LV very-large-volume VLV disease Multivariate analysis Cox regression proportional hazards model assessable patients following adverse prognostic factors high-volume metastatic burden age years prechemotherapy AFP micrograms/L and/or HCG U/L interval orchiectomy start chemotherapy weeks place treatment final outcome patients LV VLV disease presence following risk factors additional prognostic factor AFP micrograms/L HCG U/L liver metastases brain metastases bone metastases retroperitoneal tumor equal cm mediastinal tumor equal cm